The diagnostic value of adiponectin multimers in healthy men undergoing screening for prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 2, 2014, Pages 309-315

  Medina, Edward A ^a   Shi, Xiaoyu ^b   Grayson, Marcia H ^c   Ankerst, Donna P ^b,d   Livi, Carolina B ^b   Medina, Maria V ^b   Thompson Jr , Ian M ^b   Leach, Robin J ^b,c  

^a Departments of Pathology and Urology   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Departments of Cellular and Structural Biology   (United States)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ADIPONECTIN MULTIMER; POLYMER; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; EVALUATION STUDY; FAMILY HISTORY; GLEASON SCORE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEGRO; OBESITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RACE; CASE CONTROL STUDY; EARLY DIAGNOSIS; METABOLISM; NORMAL HUMAN; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RISK FACTOR; VERY ELDERLY;

ADIPONECTIN; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; EARLY DETECTION OF CANCER; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; OBESITY; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84893677638     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0574     Document Type: Article

References (32)

1. Carbone F, La Rocca C, Matarese G. Immunological functions of leptin and adiponectin. Biochimie 2012;94:2082-8.
2. Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab 2013;17: 185-96.
3. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev 2012;33: 547-94.
4. Piya MK, McTernan PG, Kumar S. Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin. J Endocrinol 2013;216:T1-T15.
5. Vansaun MN. Molecular pathways: adiponectin and leptin signaling in cancer. Clin Cancer Res 2013;19:1926-32.
6. Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun 2006;340: 1158-66.
7. Mistry T, Digby JE, Desai KM, Randeva HS. Leptin and adiponectin interact in the regulation of prostate cancer cell growth via modulation of p53 and bcl-2 expression. BJU Int 2008;101: 1317-22.
8. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S. Prostate cancer and adiponectin. Urology 2005;65:1168-72.
9. Sher DJ, Oh WK, Jacobus S, Regan MM, Lee GS, Mantzoros C. Relationship between serum adiponectin and prostate cancer grade. Prostate 2008;68:1592-8.
10. Arisan ED, Arisan S, Atis G, Palavan-Unsal N, Ergenekon E. Serum adipocytokine levels in prostate cancer patients. Urol Int 2009;82: 203-8.
11. Li H, Stampfer MJ, Mucci L, Rifai N, Qiu W, Kurth T, et al. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem 2010;56:34-43.
12. Burton A, Martin RM, Holly J, Lane JA, Donovan JL, Hamdy FC, et al. Associations of adiponectin and leptin with stage and grade of PSAdetected prostate cancer: the ProtecT study. Cancer Causes Control 2013;24:323-34.
13. Dhillon PK, Penney KL, Schumacher F, Rider JR, Sesso HD, Pollak M, et al. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2011;20:2618-27.
14. Barb D, Neuwirth A, Mantzoros CS, Balk SP. Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway. Endocr Relat Cancer 2007;14:995-1005.
15. Housa D, Vernerova Z, Heracek J, Prochazka B, Cechak P, Kuncova J, et al. Adiponectin as a potential marker of prostate cancer progression: studies in organ-confined and locally advanced prostate cancer. Physiol Res 2008;57:451-8.
16. Freedland SJ, Sokoll LJ, Platz EA, Mangold LA, Bruzek DJ, Mohr P, et al. Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. J Urol 2005;174: 1266-70.
17. Baillargeon J,PlatzEA,RoseDP,PollockBH,AnkerstDP,Haffner S, et al. Obesity, adipokines, and prostate cancer in a prospective populationbased study. Cancer Epidemiol Biomarkers Prev 2006;15:1331-5.
18. Lopez Fontana CM, Maselli ME, Perez Elizalde RF, Di Milta Monaco NA, Uvilla Recupero AL, Lopez Laur JD. Leptin increases prostate cancer aggressiveness. J Physiol Biochem 2011;67:531-8.
19. Tonelli J, Li W, Kishore P, Pajvani UB, Kwon E, Weaver C, et al. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 2004;53:1621-9.
20. Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, et al. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detectHMW adiponectin. Diabetes 2006;55: 1954-60.
21. Baessler A, Schlossbauer S, Stark K, Strack C, Riegger G, Schunkert H, et al. Adiponectin multimeric forms but not total adiponectin levels are associated with myocardial infarction in non-diabetic men. J Atheroscler Thromb 2011;18:616-27.
22. Chen MW, Ye S, Zhao LL, Wang SY, Li YX, Yu CJ, et al. Association of plasma total and high-molecular-weight adiponectin with risk of colorectal cancer: an observational study in Chinese male. Med Oncol 2012;29:3129-35.
23. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157: 120-34.
24. Serkin FB, Soderdahl DW, Cullen J, Chen Y, Hernandez J. Patient risk stratification using Gleason score concordance and upgrading among men with prostate biopsy Gleason score 6 or 7. Urol Oncol 2010; 28:302-7.
25. Liang Y, Ankerst DP, KetchumNS, Ercole B, Shah G, Shaughnessy JD Jr., et al. Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol 2011;185:104-10.
26. Ebinuma H, Miida T, Yamauchi T, Hada Y, Hara K, Kubota N, et al. Improved ELISA for selective measurement of adiponectin multimers and identification of adiponectin in human cerebrospinal fluid. Clin Chem 2007;53:1541-4.
27. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol 2013;63:800-9.
28. Texas Behavioral Risk Factor Surveillance System Combined Year Dataset, Statewide BRFSS Survey, 2002-2005. Center for Health Statistics Community Assessment Texas Department of State Health Services.
29. Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007;298: 2275-80.
30. Sullivan PW, Ghushchyan VH, Ben-Joseph R. The impact of obesity on diabetes, hyperlipidemia and hypertension in the United States. Qual Life Res 2008;17:1063-71.
31. Romero CX, Romero TE, Shlay JC, Ogden LG, Dabelea D. Changing trends in the prevalence and disparities of obesity and other cardiovascular disease risk factors in three racial/ethnic groups of USA adults. Adv Prev Med 2012;2012:172423.
32. Looker HC, Krakoff J, Funahashi T, Matsuzawa Y, Tanaka S, Nelson RG, et al. Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab 2004;89:4010-7.